Regulatory 2024-05-06 | Bulletin from the Annual General Meeting in Ascelia Pharma AB on 6 May 2024 PDF Report Presentation Webcast
Regulatory 2024-05-02 | Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study PDF Report Presentation Webcast
2024-04-18 | Ascelia Pharma Draws Down SEK 15 Million Second Tranche Under Existing Loan Facility PDF Report Presentation Webcast
2024-04-10 | Ascelia Pharma Reports SPARKLE Image Reading Completion and Expects Headline Results First Half of May 2024 PDF Report Presentation Webcast
Regulatory 2024-04-08 | Annual Report 2023: Solid Progress with Orviglance Phase 3 Patient Recruitment Completed and Headline Results Expected by May 2024 PDF Report Presentation Webcast
Regulatory 2024-03-27 | Notice of Annual General Meeting in Ascelia Pharma AB PDF Report Presentation Webcast
Regulatory 2024-02-09 | Q4 and Full Year Report 2023: Strengthened Financial Position Ahead of SPARKLE Phase 3 Study Headline Results in May PDF Report Presentation Webcast
Regulatory 2024-02-04 | Ascelia Pharma Secures Financing of up to SEK 35 Million PDF Report Presentation Webcast
2024-01-24 | Orviglance Review Article Published in Investigative Radiology PDF Report Presentation Webcast
Regulatory 2024-01-24 | Nomination Committee Appointed for AGM 2024 in Ascelia Pharma AB PDF Report Presentation Webcast
